Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-30
2007-10-30
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10467359
ABSTRACT:
The present invention relates to a pharmaceutical composition for treatment and/or prevention for urinary diseases comprising a lysophosphatidic acid (LPA) receptor regulator.As LPA receptor regulators act on urethra and prostate, compounds acting on this receptor are useful in treating urinary diseases (urinary incontinence, dysuria, etc.). For example, an LPA receptor agonist useful for treatment of urinary incontinence, while an LPA receptor antagonist is useful for treatment of dysuria, ischuria, pollakiuria, nocturia, urodynia and benign prostatic hyperplasia.
REFERENCES:
patent: 6242449 (2001-06-01), Sato et al.
patent: 0799619 (1997-10-01), None
patent: 1020190 (2000-07-01), None
patent: 1258484 (2002-11-01), None
patent: 1-125330 (1989-05-01), None
patent: 9-328469 (1997-12-01), None
patent: 10-152446 (1998-06-01), None
patent: 2000-247998 (2000-09-01), None
patent: WO96/23492 (1996-08-01), None
patent: WO99/03831 (1999-01-01), None
patent: WO99/35259 (1999-07-01), None
patent: WO 00/35954 (2000-06-01), None
patent: WO 01/60819 (2001-08-01), None
patent: WO 01/71022 (2001-09-01), None
Inoue et al., Clinical Science (1999) 96, 431-436.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
“urinary system.” The Columbia Electronic Encyclopedia, Sixth Edition. Columbia University Press., 2003. Answers.com, Jan. 18, 2006. http://www.answers.com/topic/urinary-system.
Urinary Disorders: Specific Diseases/Conditions [online], [retrieved of Jan. 18, 2006]. Retrieved from the Internet, URL;http://www.netwellness.org/healthtopics/urinary/more.cfm?categoryid=17.
Bremnor et al., Evaluation of Dysuria in Adults, American Family Physician, vol. 65, No. 8, Apr. 15, 2002, pp. 1589-1596.
Roberts et al., Evaluation of Dysuria in Men, American Family Physician, vol. 60, No. 3, Sep. 1, 1999.
Cowan et al., J. Urol. Sep. 1998; 160(3 Pt 1) : 882-6 (abstract only).
Matsuzaki et al., Steroids. Feb. 1998; 63(2): 105-10 (abstract only).
Blue et al., Br J Pharmacol. May 1995; 115(2):283-04 (abstract only).
Monus et al., Br J Exp Pathol. Feb. 1979: 60(1):72-5 (abstract only).
Santos, Webster et al, “The Molecular Pharmacology of Lysophosphatidate Signaling,” Annals of NY Academy of Sciences, XP009027816, vol. 905, 2000, pp. 232-241.
Maschberger Petra et al, “Mildly Oxidized Low Density Lipoprotein Rapidly Stimulates via Activation of the Lysophosphatidic Acid Receptor Src Family and Syk Tyrosine Kinases and Ca2+Influx in Human Platelets,” J: Biological Chem., XP002364629, vol. 275, No. 25, Jun. 23, 2000, pp. 19159-19166.
Hopper, David et al., “Facile Synthesis of Lysophospholipids Containing Unsaturated Fatty Acid Chains,” Tetrahedron Letters, XP004030993, vol. 37, No. 44, Oct. 28, 1996, pp. 7871-7874.
Fukushima Daikichi
Nakade Shinji
Anderson Rebecca
Ono Pharmaceuticals Co. Ltd.
Sughrue Mion Pllc.
LandOfFree
Pharmaceutical composition for treatment for urinary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for treatment for urinary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for treatment for urinary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3900771